McDermott Will & Emery represented Applied DNA Sciences, Inc. on the offering. Applied DNA Sciences, Inc. (Applied DNA), a leader in PCR-based DNA technologies, executed its...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Inhibikase Therapeutics in the transaction. Inhibikase Therapeutics, Inc. (Inhibikase), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Applied DNA Sciences, Inc., while Harter Secrest & Emery represented the placement agent in the transaction. Applied DNA Sciences, Inc. (Applied...
You must be a Standard 1 Year member to access this content.
McDermott represented Applied DNA Sciences, Inc. in the transaction. Applied DNA Sciences, Inc. (“Applied DNA”), a leader in PCR-based DNA technologies, announced its acquisition of Spindle...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Inhibikase Therapeutics, Inc. in the transaction. Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the...
You must be a Standard 1 Year member to access this content.
McDermott Will & Emery represented Spine Biopharma in the transaction. Spine Biopharma, Inc, a biopharmaceutical company committed to developing non-opiate, non-surgical therapies for the treatment of...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal. PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders LLP advised BioXcel LLC on the deal. BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical development company, announced the pricing of an...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders LLP advised Inhibikase Therapeutics, Inc. on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company developing therapeutics to modify the...
You must be a Standard 1 Year member to access this content.
Troutman Pepper Hamilton Sanders LLP advised Spine BioPharma, LLC on the deal. Spine BioPharma, LLC, a company committed to developing non-surgical, non-opiate therapies to treat degenerative...
You must be a Standard 1 Year member to access this content.
